- Home
- SCSC vs JANX Comparison
SCSC vs JANX Comparison
Compare SCSC & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCSC | JANX |
|---|---|---|
| Founded | 1992 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 909.7M | 890.8M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SCSC | JANX |
|---|---|---|
| Price | $35.64 | $13.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $43.00 | ★ $57.36 |
| AVG Volume (30 Days) | 251.7K | ★ 1.7M |
| Earning Date | 02-05-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.98 | N/A |
| EPS | ★ 3.25 | N/A |
| Revenue | ★ $3,023,895,000.00 | $10,000,000.00 |
| Revenue This Year | $5.40 | N/A |
| Revenue Next Year | $5.34 | N/A |
| P/E Ratio | $11.01 | ★ N/A |
| Revenue Growth | ★ 0.07 | N/A |
| 52 Week Low | $28.75 | $12.12 |
| 52 Week High | $46.25 | $38.42 |
Technical Indicators
Market Signals| Indicator | SCSC | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 33.80 | 46.25 |
| Support Level | $33.76 | $12.74 |
| Resistance Level | $45.23 | $13.61 |
| Average True Range (ATR) | 1.83 | 0.67 |
| MACD | -0.85 | 0.12 |
| Stochastic Oscillator | 10.29 | 52.05 |
Price Performance
Historical ComparisonAbout SCSC ScanSource Inc.
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Intelisys & Advisory Segment. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States and Canada, and also has its presence in Brazil, and other countries.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.